UnitedHealth Group (NYSE: UNH) reported its financial results for the first quarter ended March 31, 2026, on April 22, 2026. The healthcare conglomerate posted an 8% year-over-year increase in adjusted earnings per share (EPS), surpassing consensus analyst expectations. Total revenue for the period reached $108.5 billion, driven by expansion across both its UnitedHealthcare insurance division and its Optum health services business. Chief Executive Officer Andrew Witty attributed the results to disciplined medical cost management and the continued integration of advanced clinical technology across the enterprise.
A primary driver of the quarterly performance was the improvement in the Medical Care Ratio (MCR), which measures the percentage of premiums spent on medical claims. For the first quarter of 2026, the MCR fell to 83.2%, compared to 84.3% in the same period the previous year. This decrease indicates more efficient management of healthcare costs relative to premium income. UnitedHealthcare, the company's insurance arm, added approximately 1.2 million new members across its domestic commercial and Medicare Advantage offerings during the quarter, bringing its total served population to over 53 million individuals.
The Optum segment reported double-digit revenue growth, reaching $62.4 billion for the quarter. Optum Health, which provides direct patient care, saw a significant increase in the number of patients served under value-based care arrangements. Optum Insight, the data and analytics division, reported a backlog increase of 12% compared to the prior year, following the implementation of new artificial intelligence tools for clinical documentation and claims processing. Optum Rx, the pharmacy benefit manager, processed 415 million prescriptions in the quarter, a 5% increase year-over-year, supported by new large-group contract wins.
Based on the first-quarter results, UnitedHealth Group raised its full-year 2026 adjusted net earnings guidance to a range of $31.10 to $31.60 per share, up from the previous range of $30.75 to $31.25. Following the announcement, Argus Research upgraded UnitedHealth Group from Hold to Buy, citing the company's ability to navigate regulatory changes in Medicare Advantage and its strong cash flow generation. The company reported cash flows from operations of $7.8 billion for the quarter and returned $4.5 billion to shareholders through a combination of dividends and share repurchases.
The company also provided updates on its capital allocation strategy, noting that it remains committed to investing in its home-based care capabilities and expanding its global footprint. Chief Financial Officer John Rex stated during the earnings call that the company’s diversified portfolio allowed it to offset inflationary pressures in certain labor markets. UnitedHealth Group ended the quarter with a debt-to-total-capital ratio of 38%, maintaining its investment-grade credit profile while continuing its pace of strategic acquisitions in the primary care sector.